TDC
CYTK icon

Thompson Davis & Co’s Cytokinetics CYTK Stock Holding History

Thompson Davis & Co’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-750
Closed -$10K – 1100
2017
Q1 		$10K Buy
+750
New +$8.77K 0.01% 683
2016
Q1 		– Sell
-250
Closed -$3K – 1091
2015
Q4 		$3K Buy
+250
New +$2.45K ﹤0.01% 932

Other funds holding CYTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
LPU
Lansdowne Partners (UK) London, United Kingdom $1.87B AUM 61.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Thompson Davis & Co's CYTK Position: Q2 2017 in Review

Thompson Davis & Co sold out of Cytokinetics (CYTK) in Q2 2017, closing a stake of 750 shares — an estimated $10K sold.

Thompson Davis & Co first reported a position in CYTK in Q4 2015 and held it in 2 quarters. The position peaked at $10K in Q1 2017. 136 funds tracked by Wall St. Rank hold CYTK as of Q2 2017.

  • Thompson Davis & Co reported no remaining Cytokinetics position as of Q2 2017 after selling out during the quarter.
  • Thompson Davis & Co sold 750 Cytokinetics shares in Q2 2017, an estimated $10K.
  • Thompson Davis & Co first reported a position in Cytokinetics in Q4 2015 and held it in 2 quarters.
  • Thompson Davis & Co's Cytokinetics position peaked at $10K in Q1 2017.
  • 136 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2017.

Based on Thompson Davis & Co's 13F filing for Q2 2017, filed 10 Aug 2017.